Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase IB study of PKC412, an oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicni and Cytarabine (DA) Induction and High Dose cytarabine consolidation in newly diagnosed adult patients with acute myeloid leukemia (AML under age 61)

Phase IB study of PKC412, an oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicni and Cytarabine (DA) Induction and High Dose cytarabine consolidation in newly diagnosed adult patients with acute myeloid leukemia (AML under age 61). Blood. 2006; 108:51a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.